CMRAW
Income statement / Annual
Last year (2022), Comera Life Sciences Holdings, Inc.'s total revenue was $633,102.00,
an increase of 97.95% from the previous year.
In 2022, Comera Life Sciences Holdings, Inc.'s net income was -$18.38 M.
See Comera Life Sciences Holdings, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$633,102.00
|
$319,832.00
|
$442,919.00
|
| Cost of Revenue |
$210,390.00 |
$161,008.00 |
$104,407.00 |
| Gross Profit |
$422,712.00 |
$158,824.00 |
$338,512.00 |
| Gross Profit Ratio |
0.67 |
0.5 |
0.76 |
| Research and Development
Expenses |
$1.74 M
|
$1.75 M
|
$1.26 M
|
| General & Administrative
Expenses |
$10.65 M
|
$3.94 M
|
$1.20 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$10.65 M
|
$3.94 M
|
$1.20 M
|
| Other Expenses |
$0.00 |
-$76,738.00 |
$2,033.00 |
| Operating Expenses |
$12.39 M |
$5.69 M |
$2.47 M |
| Cost And Expenses |
$12.60 M |
$5.86 M |
$2.57 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$20,391.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$93,947.00
|
$88,819.00
|
$89,749.00
|
| EBITDA |
-$17.89 M
|
-$5.36 M
|
-$2.04 M
|
| EBITDA Ratio |
-28.25 |
-17.54 |
-4.6 |
| Operating Income Ratio
|
-18.91
|
-17.31
|
-4.8
|
| Total Other
Income/Expenses Net |
-$6.03 M
|
$83,850.00
|
$2,033.00
|
| Income Before Tax |
-$18.00 M |
-$5.45 M |
-$2.13 M |
| Income Before Tax Ratio
|
-28.44
|
-17.05
|
-4.8
|
| Income Tax Expense |
$0.00 |
-$160,588.00 |
-$116,548.00 |
| Net Income |
-$18.38 M |
-$5.29 M |
-$2.13 M |
| Net Income Ratio |
-29.03 |
-16.54 |
-4.8 |
| EPS |
-1.76 |
-0.28 |
-0.11 |
| EPS Diluted |
-1.76 |
-0.28 |
-0.11 |
| Weighted Average Shares
Out |
$10.45 M
|
$19.09 M
|
$19.09 M
|
| Weighted Average Shares
Out Diluted |
$10.45 M
|
$19.09 M
|
$19.09 M
|
| Link |
|
|
|
